1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Cannabinoid Receptor
  4. Cannabinoid Receptor Isoform

Cannabinoid Receptor

 

Cannabinoid Receptor Related Products (269):

Cat. No. Product Name Effect Purity
  • HY-15443
    AM251
    Antagonist 99.09%
    AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM.
  • HY-110004
    ACEA
    Agonist
    ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory.
  • HY-153800
    Monlunabant
    Antagonist 99.89%
    Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with Ki of 0.3 nM and 613 nM.
  • HY-10013
    Taranabant
    Inhibitor 99.06%
    Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
  • HY-B1161A
    S-Methoprene
    Antagonist 98.58%
    S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult. S-Methoprene is also a CB(1) receptor ligand and inhibits the binding of the CB1 receptor antagonist [3H]CP-55940 to the CB1 receptor (IC50: 19.31 μM).
  • HY-113591
    CB2 receptor agonist 10
    Activator ≥99.0%
    CB2 receptor agonist 10 is a CB2 receptor agonist with a Ki of 3.7 nM for hCB2, a Ki of 110 nM for hCB1, and an EC50 of 0.52 nM for hCB2.
  • HY-W775306
    Cannabidivarinic acid
    Ligand
    Cannabidivarinic acid (CBDVA), the carboxylic acid precursor of Cannabidivarin(CBDV), is a non-psychoactive cannabinoid found in Cannabis with anti-inflammatory properties.
  • HY-W036121
    (1H-Indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
    99.97%
    (1H-Indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144 Impurity 3) is a precursor in the synthesis of synthetic cannabinoids.
  • HY-159115
    ART26.12
    99.57%
    ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin (HY-17371)-induced pain through lipid modulation and cannabinoid receptor activation.
  • HY-16642A
    LY2828360
    Agonist 99.50%
    LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.
  • HY-111110
    Olorinab
    Agonist 99.29%
    Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist, with an EC50 of 6.2 nM for hCB2.
  • HY-156831
    Lixosicone
    Inhibitor 99.39%
    Lixosicone is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). Lixosicone plays an important role in Cannabis use disorder (CUD).
  • HY-103335
    O1918
    Antagonist
    O1918 is a selective non-CB1 receptor and GPR18 antagonist.
  • HY-130311
    2-Linoleoyl glycerol
    Inhibitor
    2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG).
  • HY-14791A
    (±)-Ibipinabant
    Antagonist 99.30%
    (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
  • HY-116418
    Virodhamine
    Modulator ≥98.0%
    Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases.
  • HY-148137
    CB1 agonist 1
    Agonist 99.84%
    CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders.
  • HY-110036A
    GW405833 hydrochloride
    Agonist 99.59%
    GW-405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist with an EC50 of 50.7 nM. GW-405833 hydrochloride also behaves as a noncompetitive CB1 antagonist. GW-405833 hydrochloride suppresses inflammatory and neuropathic pain.
  • HY-B0151S2
    Pregnenolone-d4-1
    Inhibitor 99%
    Pregnenolone-d4-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].
  • HY-15451
    MDA 19
    Agonist 99.26%
    MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.